PRESS RELEASE: GenEmbryomics adds final Board Director in lead up to Nasdaq Listing
GenEmbryomics Prepares for US National Exchange Listing with Appointment of a further Independent US-Based Director
MELBOURNE, Australia, 18 March, 2024 – GenEmbryomics (Nasdaq: XGEN upon listing), a medical genetics company with world-leading intellectual property, today announced the appointment of a further independent director to its Board. This strategic move is part of the Company’s preparation for listing on a major US national exchange, underlining its commitment to global expansion and enhancing corporate governance standards.
“We are thrilled to welcome San Diago based Saadia Basharat to our Board of Directors at this pivotal time,” said Paul Viney, Chairman of GenEmbryomics. Her appointment further strengthens our Board with directors who bring a wealth of experience and expertise in healthcare, biotechnology, and strategic business development. We are confident that her contribution will be invaluable as we continue to advance our mission and prepare for our next phase of growth.”
Nick Murphy, PhD, Founder and CEO of GenEmbryomics, said, “The inclusion of Saadia to our board is a further significant milestone for GenEmbryomics. Saadia’s deep understanding of the pharmaceutical and biotech industries, combined with her expertise in program strategy and business development, will undoubtedly enhance our capabilities in navigating the complex landscape of medical genetics. She will play a critical role in guiding our strategic direction as we move towards our US national exchange listing.”
Saadia Basharat, Principal at Alacrita’s US West Coast consulting business has a decade of experience in tech transfer and consulting and has been pivotal in supporting biotech and pharma companies through critical growth junctures. Her expertise spans program prioritization, disease area and indication prioritization, and partnering strategy. Saadia’s academic background includes an Honours degree in Biomedical Informatics, a Master of Science degree in Molecular Medicine, and a PhD in Neuroendocrinology from Imperial College.
The appointment of Ms. Basharat will further strengthen GenEmbryomics’ industry position, driving forward its strategic initiatives and enhancing its governance as the Company continues on its journey towards a US national exchange listing.
To learn more about GenEmbryomics or its GenomeScreen testing, please visit the Company’s website at http://www.genembryomics.com.
About GenEmbryomics
GenEmbryomics is a medical and genetic testing company headquartered in Melbourne, Australia with a global footprint around the world. The Company’s focus is on providing the most up-to-date genetic testing and profiling for embryos prior to implantation. Additional information can be found on the Company’s website by visiting http://www.genembryomics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the current beliefs and expectations of GenEmbryomics’ management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.
Contact
Dave Gentry
RedChip Companies Inc.
[email protected]
1-800-733-2447
Paul Viney
Chairman
GenEmbryomics Limited
[email protected]
+61411282401
